Dear Speratum Biopharma Community,
When I founded Speratum Biopharma, my vision was simple yet ambitious: to transform groundbreaking research into precise, life-changing therapies for cancer patients who need them most. My journey as a scientist began over 15 years ago, driven by a fascination with molecular biology and a determination to address some of the most complex challenges in oncology. Alongside our incredible team, I am proud to lead Speratum with a singular focus on advancing microRNA-based therapeutics that target cancer at its molecular roots.
As we prepare to embark on clinical trials with our lead candidate, NM-198, I am inspired by the progress we’ve made and the extraordinary potential of our proprietary platforms, Nano-In™ and No-Pass™. These technologies represent years of innovation, collaboration, and dedication to redefining how cancer is treated.
Pioneering Precision Oncology
The foundation of Speratum Biopharma lies in a commitment to excellence in science and a relentless pursuit of solutions for patients battling aggressive and treatment-resistant cancers. NM-198, our first therapeutic candidate, is a testament to this vision. By leveraging the power of microRNA-198, we aim to deliver targeted therapies that minimize off-target effects while maximizing efficacy—a critical breakthrough for solid tumors.
Establishing Speratum Biopharma required more than just scientific rigor. It demanded a team capable of translating research into actionable treatments. I am fortunate to work alongside talented scientists, clinicians, and business leaders who share my belief that precision medicine is the key to revolutionizing cancer care.
Creating Impact Through Collaboration
I have always believed that science is never done in isolation. To truly make a difference, we need a network of collaborators, advocates, and supporters. This year, Speratum has forged partnerships with academic institutions, investors, and leading experts in the field to accelerate the development of our pipeline. These partnerships not only expand our reach but also strengthen our ability to deliver meaningful results.
Our proprietary platforms, Nano-In™ and No-Pass™, are the product of years of innovation and dedication. These delivery systems are specifically designed to optimize the safety and effectiveness of our microRNA therapies, ensuring they reach their intended targets with precision.
Our Vision for 2024 and Beyond
As we move forward, I am reminded daily of why Speratum Biopharma exists: to offer hope to patients and families facing the uncertainties of cancer. With the anticipated launch of our clinical trials, we are entering an exciting phase of growth and discovery.
Looking ahead, our goals are clear:
Join Us on This Journey
Speratum Biopharma is more than a company—it is a movement to redefine what is possible in oncology. Together, we can pioneer therapies that not only treat cancer but also improve the quality of life for patients worldwide.
On behalf of the entire Speratum team, I invite you to be part of our mission. Whether you are a researcher, investor, patient, or advocate, your support fuels our progress and brings us closer to a future where cancer is no longer undefeatable.
With gratitude,
Dr. Christian Marín Müller, MS, PhD
Founder, Director, and CEO
Speratum Biopharma
Transforming Cancer Care with Precision and Purpose
At Speratum Biopharma, we are redefining the future of cancer treatment with a clear mission: to deliver hope through groundbreaking advancements in precision oncology. Our work is driven by innovation, compassion, and a relentless commitment to making a difference in the lives of patients facing some of the most aggressive and hard-to-treat cancers.
Speratum isn’t just a biotechnology company -we’re a team of passionate innovators dedicated to unlocking the potential of miRNA-based therapies using our proprietary Nano-In and Nano-Pass Platforms. These cutting-edge technologies enable us to develop targeted, effective treatments that aim to change the trajectory of cancer care.
Every day, our work transforms hope into action for patients and their families.
Be part of a team advancing state-of-the-art nucleic acid therapies and redefining oncology solutions.
Work alongside a seasoned team of experts committed to pushing the boundaries of medicine.
Join a community of dedicated professionals who believe in the power of teamwork to achieve extraordinary results.
At Speratum, we value your potential and provide opportunities for growth and advancement as we work together to achieve our mission.
At Speratum Biopharma, we believe that science and innovation, combined with purpose and hope, drive the breakthroughs that change lives. We nurture a collaborative and agile work environment where every team member feels empowered to make a difference.
We focus on results and actions rather than processes, allowing us to remain flexible and innovative. By fostering creativity, transparency, and teamwork, we ensure that great ideas lead to meaningful outcomes for patients who need them the most.
Together, we are advancing science, delivering hope, and creating a future where cancer therapies are more targeted, effective, and accessible. Join us on this journey to inspire and deliver hope to patients worldwide.
We process your personal information to measure and improve our sites and service, to assist our marketing campaigns and to provide personalised content and advertising. By clicking the button on the right, you can exercise your privacy rights. For more information see our privacy notice